Statin-ezetimibe combination drugs greatly expanded their influence in Korea’s dyslipidemia treatment market. Their total prescription amount increased by over threefold in the past 5 years, and its annual market size exceeds KRW 750 billion. In the market, rosuvastatin-ezetimibe combinations drove market growth, and the bulk of generic atorvastatin-ezetimibe combination drugs that were recently released also supported the strong growth.

◆Sales of statin-ezetimibe combos rise from KRW 228.4 billion to KRW 750.4 billion in 5 yrs

According to the market research institution UBIST on the 31st, outpatient prescriptions of statin-ezetimibe combination drugs reached KRW 750.4 billion last